JQ1, a BET‐bromodomain inhibitor, inhibits human cancer growth and suppresses PD‐L1 expression
Sign Up to like & getrecommendations! Published in 2019 at "Cell Biology International"
DOI: 10.1002/cbin.11139
Abstract: Most traditional cytotoxic chemotherapeutic agents have poor aqueous solubility and significant toxicity. Hence, there is a need to develop molecule‐targeted drugs. Programmed death‐ligand 1 (PD‐L1) is associated with the prognosis of several cancer types, and… read more here.
Keywords: cell; bromodomain inhibitor; jq1; cancer ... See more keywords
Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK‐8628 in malignant pleural mesothelioma xenografts
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Cancer"
DOI: 10.1002/ijc.30412
Abstract: It has recently been reported that a large proportion of human malignant pleural mesothelioma (MPM) cell lines and patient tissue samples present high expression of the c‐MYC oncogene. This gene drives several tumorigenic processes and… read more here.
Keywords: mesothelioma; otx015; inhibitor otx015; bromodomain inhibitor ... See more keywords
Interrogating bromodomain inhibitor resistance in KMT2A-rearranged leukemia through combinatorial CRISPR screens
Sign Up to like & getrecommendations! Published in 2023 at "Proceedings of the National Academy of Sciences of the United States of America"
DOI: 10.1073/pnas.2220134120
Abstract: Significance Using combinatorial loss-of-function CRISPR screens, our study revealed a Bromo- and extra-terminal domain inhibitors (BETi) resistance network in KMT2A-r leukemia. Based on these findings, we have also revealed a corresponding synergy treatment regimen, significantly… read more here.
Keywords: inhibitor resistance; crispr screens; interrogating bromodomain; resistance ... See more keywords
Abstract 1382: A novel BET family bromodomain inhibitor NHWD-870 represents a promising therapeutic agent for a broad spectrum of cancers
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-1382
Abstract: Small molecule inhibitors of the bromodomain and extraterminal domain (BET) proteins have emerged as a promising option for cancer therapy. NHWD-870 is a potent and selective BET family bromodomain inhibitor and only binds bromodomains of… read more here.
Keywords: family bromodomain; bromodomain inhibitor; nhwd 870; cancer ... See more keywords
Abstract 2475: Bromodomain inhibitor: MT1 and its potential role in modulation of prostate cancer progression
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2475
Abstract: Bromodomains (BD) are epigenetic readers of histone acetylation involved in chromatin remodeling and transcriptional regulation of protooncogene cellular myelocytomatosis (c- Myc) and other genes. Because c-Myc cannot be directly targeted by small molecular inhibitors due… read more here.
Keywords: prostate cancer; growth; inhibitor; myc ... See more keywords
Bromodomain Inhibitor JQ1 Provides Novel Insights and Perspectives in Rhabdomyosarcoma Treatment
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23073581
Abstract: Rhabdomyosarcoma (RMS) is the most common type of pediatric soft tissue sarcoma. It is classified into two main subtypes: embryonal (eRMS) and alveolar (aRMS). MYC family proteins are frequently highly expressed in RMS tumors, with… read more here.
Keywords: provides novel; jq1 provides; treatment; bromodomain inhibitor ... See more keywords